Register Login

Intellia Therapeutics Inc (NTLA)

  • Event
  • Aug. 04, 2022, 11:46 UTC

(90% Positive) INTELLIA THERAPEUTICS, INC. (NTLA) Announces Enrollment Update for results Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 5:57 p.m.

    📋 INTELLIA THERAPEUTICS, INC. (NTLA) - Clinical Trial Update

    Filing Date: 2022-08-04

    Accepted: 2022-08-04 07:46:30

    Event Type: Clinical Trial Update

    Event Details:

    Intellia Therapeutics Inc (NTLA) Announces Clinical Trial Update Intellia Therapeutics Inc (NTLA) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: results, data
    • Clinical Stage: Phase 1 study, Phase 1
    • Collaboration: CRISPR
      • targeting CD30 for the treatment of CD30-expressing hematologic cancers, including relapsed or refractory classical Page 4 of 9 intelliatx.com Hodgkin lymphoma (cHL). NTLA-6001

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Intellia Therapeutics Inc
    • CIK: 0001652130
    • Ticker Symbol: NTLA
    • Period End Date: 2022-08-04
    • Document Type: 8-K

Search

News categories